A Multidisciplinary Team Approach Challenges and Best Practices in Cushing Disease.

Slides:



Advertisements
Similar presentations
עדכונים בטיפול במחלת קושינג »ד"ר גבי דיקשטין »ביה"ח בני ציון »חיפה.
Advertisements

Clinical case 2003… A 30 year-old woman…...admitted to our hospital due to obesity and diabetes mellitus...
Morbidity and Mortality Conference Ann Marie Lam, PGY-2 Emory University School of Medicine Family Medicine Residency Program October 14 th, 2010.
Cushing’s Syndrome Britni Hebert PGY 2 4/9/10 Notes located in presenter note section below each slide.
Beyond pituitary surgery: Radiosurgery vs. Adrenalectomy vs Medical Treatment when Cushing’s disease persists or recurs Theodore C. Friedman, M.D., Ph.D.
Check your knowledge in… Adrenal diseases. Which treatment is indicated in case of hyperaldosteronism due to adrenal hyperplasia? 1.Medical treatment.
Trial of posaconazole therapy for chronic pulmonary aspergillosis
Multimodal Management of Opioid-Induced Constipation
The Patient Experience With Systemic Lupus Erythematosus
Expert Perspectives on New Treatment Options for Parkinson Disease Psychosis.
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
MLAB 2401: Clinical Chemistry Keri Brophy-Martinez
Monitoring and Modifying Treatment in PAH
Challenges and Opportunities in the Management of ANCA-Associated Vasculitis.
Program Themes. Consulting on Common Concerns in PAH: How Would You Manage These Patients?
Managing the Patient With Tuberous Sclerosis Complex
Fundamental Concepts in the Diagnosis of Advanced NSCLC
Goals of Therapy for Patients With UC
Beyond Supportive Care for Lower-Risk Myelodysplastic Syndrome
Patient 1: 53-Year-Old Man With CVD Risk Factors
Ask the Onychomycosis Expert, Part 2
Ask the Onychomycosis Expert, Part 1
Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.
COORDINATED CARE IN CUSHING DISEASE
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Continuing the Advances in Relapsed/Refractory CLL: New Data, New Paradigms.
The Nurse View: Overcoming Challenges Associated With Cancer Immunotherapy.
IL-17 Inhibitors in the Management of Psoriatic Disease
Patient Stories: Transitioning to Oral Prostacyclin Pathway Therapy
HCV Protease Inhibitors in Clinical Practice
62-year-old Man With Unstable Angina
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.
The Nurse View: Targeted Therapies for the Patient With Metastatic Colorectal Cancer.
Multidisciplinary Perspectives on Interstitial Lung Diseases
Clinical Pearls on the Management of Immune-Mediated Adverse Events Affecting the Genitourinary Tract.
Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.
Immunotherapy for cSCC
Use of Mifepristone for Prevention of Adrenal Insufficiency Following
Personalized Therapy in Relapsed or Refractory CLL
Advancing the Treatment of IBD With Biologics
When Is Biologic Therapy Appropriate for HS?
Nurse View: Practice Pearls in Advanced Pancreatic Adenocarcinoma
Live From MDS New Developments in Parkinson's Disease Psychosis
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.
Implications of Emerging Treatments for Beta-Thalassemia
Theodore C. Friedman, M.D., Ph.D. Symposium on Cushing’s Syndrome
Clinical Issues in AIP:
Treatment of Locally Advanced Pancreatic Cancer
EGPA.
Breaking News in Pemphigus Vulgaris and the Latest Updates for Your Practice.
Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.
Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC
Patient Questions and Expert Answers in Psoriasis:
HCV Protease Inhibitors in Clinical Practice
Oral Prostacyclin Pathway Agents in PAH
Incorporating Prostacyclins Into Practice
Treating Atypical Hemolytic Uremic Syndrome A Case Discussion
The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.
Educational Objectives
Prostacyclin Pathway Agents in Action
Breast Multidisciplinary Team Meetings
PCSK9 Inhibitors and Statin Intolerance
PAH Pathways: What Do the Data Tell Us?”
The Building Blocks of Homocystinuria and Homocysteinemia Management
Ask the Psoriasis Expert
Disease Activity Cutoffs for ACR-Recommended RA Disease Activity Measure
Case Study #1. Management of Heart Failure With Comorbidities: Challenging Cases for the Cardiologist.
Case-Based Look at Hyperkalemia Identification, Diagnosis, and Management.
Interprofessional Approach to Managing Adverse Events of PI3K Inhibitors.
Presentation transcript:

A Multidisciplinary Team Approach Challenges and Best Practices in Cushing Disease

Program Goals

Patient Case 39-Year-Old Woman

Patient Case (cont)

Cushing Disease Clinical Features

Cushing Disease Biochemical Diagnosis

Patient Case Laboratory Findings

Establishing the Source of ACTH Excess

Managing Patient Expectations Post-Operatively

Patient Case Post-Op Course

Patient Case 3 Years Later…

Does the Patient Have Recurrent Cushing Disease?

Recurrent Cushing Disease Treatment Targets and Options

Adrenal Steroidogenesis Inhibitors*

Cabergoline* Dopamine Agonist

Absolute Change in UFC Levels From Baseline to Month 6 With Pasireotide

Pasireotide Adverse Events Hyperglycemia

Mifepristone

Mifepristone Adverse Events and Monitoring

Emerging Agents Target Adrenal Steroidogenesis

Radiation Therapy and Radiosurgery

Bilateral Adrenalectomy